Verified ComparisonLast updated: 23 April 2026
Tirzepatide vs Liraglutide
Tirzepatide combines GLP-1 and GIP receptor agonism, while liraglutide acts only on GLP-1. The dual mechanism gives tirzepatide an edge in metabolic studies.
Tirzepatide
Metabolic
4.6/ 5
A
Liraglutide
Metabolic
4.1/ 5
A−
Editor's note
Tirzepatide produces higher weight loss in head-to-head data. Liraglutide has the longest clinical track record.
| Criterion | Tirzepatide | Liraglutide |
|---|---|---|
| Mechanism | GLP-1 + GIP | GLP-1 only |
| Weight loss in trials | Robust, superior to GLP-1 alone | Established, lower than tirzepatide |
| Length of clinical use | Growing | Decades |
| Regulatory status (AU) | Approved | Approved |
| Half-life | Long (weekly dosing) | Long (weekly or daily) |
Frequently asked questions
Both tirzepatide and liraglutide are approved for weight management and type 2 diabetes.
Want to read the full reviews?